化合物简介
Rucaparib (AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent. Rucaparib is the first-in-class clinical candidate targeting the DNA repair enzyme poly-ADPribose polymerase-1 (PARP-1), and was first synthesised as part of a collaboration between scientists working in Northern Institute of Cancer Research and Medical School of Newcastle University, alongside Agouron Pharmaceuticals (San Diego). It is being developed by Clovis Oncology.
基本信息
中文名称
瑞卡帕布
英文名称
Rucaparib
中文别名
8-氟-1,3,4,5-四氢-2-[4-[(甲基氨基)甲基]苯基]-6H-吡咯并[4,3,2-EF][2]苯并氮杂卓-6-酮
英文别名
8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one、6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]、Kinome_3180、RUCAPARIB、UNII-8237F3U7EH、8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one
CAS号
283173-50-2
分子式
C19H18FN3O
分子量
323.364
精确质量
323.143
PSA
56.92
LOGP
3.699
编号系统
UNII
8237F3U7EH
物化性质
密度
1.281 g/cm3
沸点
625.248ºC at 760 mmHg
闪点
331.938ºC
安全信息
海关编码
2933990090
合成路线
上游原料
共找到7个上游原料 >